Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.
Bottom Line:
Secondary outcomes were plasma VEGF-A and central foveal thickness.Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 ± 61.89 pg/mL) when compared with group 2 (626.09 ± 279.27 pg/mL; P = .036) and group 3 (735.48 ± 216.43 pg/mL; P = .013), but similar levels to group 4 (235.81 ± 33.99 pg/mL; P = .215).This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients.
View Article:
PubMed Central - PubMed
Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: frezendef@hotmail.com.
Show MeSH
Related in: MedlinePlus |
![]() Related In:
Results -
Collection
License getmorefigures.php?uid=PMC4389631&req=5
Figure 3: Graph showing omega-3 supplementation and systemic vascular endothelial growth factor (VEGF) A concentrations in wet age-related macular degeneration and control patients. Plasma VEGF levels demonstrating no significant difference between group 4 (control; n = 8) and group 1 (anti-VEGF plus omega-3; n = 9; P = .7361), group 2 (anti-VEGF alone; n=6; P=.6194), and group 3 (treatment naïve, starting on anti-VEGF; n = 7; P = .9474, t test). Mentions: Analysis of plasma levels of VEGF-A revealed no significant change between groups (P = .736; Figure 3). Similarly, although values for CFT tended toward improvement, no significant benefit was noted with omega-3 supplementation in the sample population investigated in this pilot study (P = .211; Figure 4). |
View Article: PubMed Central - PubMed
Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: frezendef@hotmail.com.